Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222803 | 0.83 | CYP8B1 (0.43) | HDAC1SLC29A1MEN1KMT2ANPSR1 | |
| SCHEMBL1224645 | 0.80 | KCNH2 (0.44) | DPP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1222676 | 0.78 | CTSL (0.40) | DPP4 | |
| SCHEMBL2945463 | 0.73 | KCNH2 (0.44) | SMN1; SMN2 | |
| SCHEMBL2952599 | 0.71 | KCNH2 (0.42) | — | |
| SCHEMBL16611411 | 0.71 | MEN1 (0.69) | DPP4MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL1224674 | 0.71 | CHRNB2 (0.45) | — | |
| SCHEMBL5750818 | 0.70 | GRM5 (0.41) | HDAC1MEN1KMT2ANPSR1NPC1 | |
| SCHEMBL5232102 | 0.70 | ALDH1A1 (0.47) | DPP4PTGDR2MEN1KMT2ANPSR1 | |
| SCHEMBL29013207 | 0.70 | PTGDR2 (0.42) | DPP4HDAC1PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | DPP4 1336/4885HDAC1 473/4885PTGDR2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.